Howard Kim, PhD

Vice President, Cell Therapy

PhD, University of Toronto


Dr. Kim leads NYSCF’s cell therapy program, including our macular degeneration clinical research program. He joined NYSCF in 2018. He is an expert in regenerative medicine and cell therapy manufacturing.

Dr. Kim completed his PhD in medical science and biomedical engineering at the University of Toronto. He then worked for seven years at the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto. He has considerable experience as both scientific and managerial leads of high-impact research projects advancing cell therapy technologies in collaboration with academic, government, small biotech, and large-pharma industry partners.

At NYSCF, he is leading our program to create clinical-grade cells using our Good Manufacturing Practices (GMP) facility, with the aim of establishing a pipeline for personalized cell therapies. This includes the development of a personalized cell replacement therapy to treat age-related macular degeneration, a leading form of blindness, which his team is now advancing towards a clinical trial.